The Role of Monounsaturated and Polyunsaturated Fatty Acids: Oleic and Linoleic in Type 2 Diabetes Management

Abstract

Dietary monounsaturated fatty acids (MUFAs) and polyunsaturated fatty acids (PUFAs)—particularly oleic acid (OA) and linoleic acid (LA)—are increasingly recognized as critical modulators of metabolic health and disease prevention. A growing body of evidence from clinical trials and experimental studies indicates that diets enriched in these unsaturated fats can improve insulin sensitivity, reduce systemic inflammation, and favorably alter lipid profiles compared to diets high in saturated fats. However, a limited number of studies report contradictory findings regarding the role of linoleic acid, particularly concerning lipid modulation and inflammation. Mechanistically, oleic and linoleic acids enhance insulin signaling through the activation of the PI3K/Akt/GLUT4 pathway, thereby promoting glucose uptake, while simultaneously suppressing pro-inflammatory cascades such as NF-κB and JNK. These dual actions highlight their potential efficacy in mitigating metabolic dysfunction in type 2 diabetes mellitus (T2DM). Despite consistent findings supporting their beneficial effects on glycemic control, debate persists regarding optimal intake levels, dose–response relationships, and long-term outcomes. This review synthesizes current knowledge, outlines dietary sources and intake guidelines, and identifies critical gaps in the research. Overall, oleic and linoleic acids demonstrate significant metabolic and anti-inflammatory benefits, positioning them as promising dietary components for T2DM management. However, standardized study designs and longitudinal investigations are required to clarify their translational relevance and establish evidence-based recommendations for clinical practice.